Document is current
Any future updates will be listed below
-
Authors
Attal, Sepideh
Kemner, Jason
Alvir, Jose
Barth, Sebastian
Schuessler, Sofia
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 18 March 2024
First Online: 13 April 2024
Declarations
:
: Sepideh Attal, Jason Kemner, Jose Alvir, are employees of Pfizer and own stock and/or stock options. Sebastian Barth is an employee of IQVIA Commercial GmbH & Co. OHG, which received funding from Pfizer to assist in the conduct of this study and for manuscript development. Sofia Schuessler worked at IQVIA GmbH & Co. OHG at the time of the study and was a paid consultant to Pfizer in connection with this study.
: The database used for this study includes only anonymized data in compliance with the provisions set forth in the applicable data protection laws. German law allows the use of anonymous electronic medical records for research purposes under certain conditions. In accordance with this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Since all patients were only queried as aggregates and no protected health information was available for queries, no institutional review board approval was required for the use of this database or the completion of this study. IQVIA was contracted by Pfizer in connection with this study. Pfizer did not have permission to access the IQVIA<sup>TM</sup> LRx database at any time during the study, but rather received aggregated results from the database.
